{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:45:52Z","timestamp":1793853952006,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008593","name":"European Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.chest.2024.01.045","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T01:22:30Z","timestamp":1706836950000},"page":"61-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["The Efficacy and Safety of Inhaled Antibiotics for the Treatment of Bronchiectasis in Adults"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-2141","authenticated-orcid":false,"given":"Ricardo","family":"Cordeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-0653","authenticated-orcid":false,"given":"Hayoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-2874","authenticated-orcid":false,"given":"Charles S.","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.chest.2024.01.045_bib1","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1164\/rccm.201302-0240ED","article-title":"Microbes in bronchiectasis: the forest or the trees?","volume":"187","author":"Harris","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.01.045_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01953-2017","article-title":"The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis","volume":"51","author":"Ara\u00fajo","year":"2018","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.chest.2024.01.045_bib3","first-page":"1602","article-title":"A\u00a0comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.chest.2024.01.045_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-018-0629-1","article-title":"Bronchiectasis: an emerging global epidemic","volume":"18","author":"Chotirmall","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"12","key":"10.1016\/j.chest.2024.01.045_bib5","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"9842","key":"10.1016\/j.chest.2024.01.045_bib6","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.chest.2024.01.045_bib7","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2024.01.045_bib8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2024.01.045_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13543784.2018.1439919","article-title":"Inhaled medication therapy for bronchiectasis: status quo and the next frontier","volume":"27","author":"Chen","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.chest.2024.01.045_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J\u00a0Cyst Fibros"},{"issue":"243","key":"10.1016\/j.chest.2024.01.045_bib11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/adc.45.243.605","article-title":"Aerosol therapy in cystic fibrosis","volume":"45","author":"Mearns","year":"1970","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1016\/j.chest.2024.01.045_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.chest.2024.01.045_bib13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis","volume":"7","author":"Laska","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2024.01.045_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00608-2020","article-title":"Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies","volume":"56","author":"Crichton","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2024.01.045_bib15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.chest.2024.01.045_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2014-205918","article-title":"Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores","volume":"70","author":"Quittner","year":"2015","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.chest.2024.01.045_bib17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1164\/ajrccm.156.2.9607083","article-title":"Validation of the St. George\u2019s Respiratory Questionnaire in bronchiectasis","volume":"156","author":"Wilson","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2024.01.045_bib18","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019"},{"key":"10.1016\/j.chest.2024.01.045_bib19","first-page":"RCT4267","article-title":"RCT abstract\u2014the efficacy and safety of colistimethate sodium delivered via the I-neb in bronchiectasis: the PROMIS-I randomized controlled trial","volume":"58","author":"Haworth","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2024.01.045_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2024.01.045_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2024.01.045_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.chest.2024.01.045_bib23","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.chest.2024.01.045_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A\u00a0randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2024.01.045_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1345\/aph.1E099","article-title":"Inhaled tobramycin in non\u2013cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa","volume":"39","author":"Drobnic","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.chest.2024.01.045_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01451-2020","article-title":"Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study","volume":"57","author":"Loebinger","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2024.01.045_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2022.07.007","article-title":"A\u00a0double-blind randomized placebo-controlled phase 3 trial of tobramycin inhalation solution in adults with bronchiectasis with Pseudomonas aeruginosa infection","volume":"163","author":"Guan","year":"2023","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.chest.2024.01.045_bib28","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"189","author":"Haworth","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2024.01.045_bib29","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.chest.2024.01.045_bib30","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0954-6111(99)90090-2","article-title":"Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa","volume":"93","author":"Orriols","year":"1999","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2024.01.045_bib31","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2024.01.045_bib32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2024.01.045_bib33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12931-022-02243-y","article-title":"Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis","volume":"23","author":"Terpstra","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.chest.2024.01.045_bib34","series-title":"Safety and tolerability study of 2 dose level of ArikayceTM in patients with bronchiectasis and chronic infection due to Pseudomonas aeruginosa. NCT00775138. ClinicalTrials.gov","year":"2008"},{"key":"10.1016\/j.chest.2024.01.045_bib35","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.chest.2024.01.045_bib36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/15412555.2012.733463","article-title":"Do we know the minimal clinically important difference (MCID) for COPD exacerbations?","volume":"10","author":"Chapman","year":"2013","journal-title":"COPD"},{"issue":"1","key":"10.1016\/j.chest.2024.01.045_bib37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1081\/COPD-200050647","article-title":"Minimal clinically important difference\u2014exacerbations of COPD","volume":"2","author":"Calverley","year":"2005","journal-title":"COPD"},{"issue":"3","key":"10.1016\/j.chest.2024.01.045_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S2213-2600(18)30456-9","article-title":"A\u00a0new dawn: inhaled antibiotics for patients with bronchiectasis","volume":"7","author":"Grimwood","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.chest.2024.01.045_bib39","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17476348.2018.1503540","article-title":"Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis\u2014experiences from recent clinical trials","volume":"12","author":"Paredes Aller","year":"2018","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.chest.2024.01.045_bib40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cct.2017.05.007","article-title":"The RESPIRE trials: two phase III, randomized, multicentre, placebo-controlled trials of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis","volume":"58","author":"Aksamit","year":"2017","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"10.1016\/j.chest.2024.01.045_bib41","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2020","article-title":"Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies","volume":"56","author":"Chalmers","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2024.01.045_bib42","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00777-2021","article-title":"Heterogeneity of treatment response in bronchiectasis clinical trials","volume":"59","author":"Sibila","year":"2022","journal-title":"Eur Respir J"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224001399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224001399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T23:41:14Z","timestamp":1721173274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369224001399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0012369224001399"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2024.01.045","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Efficacy and Safety of Inhaled Antibiotics for the Treatment of Bronchiectasis in Adults","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2024.01.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}